No profile data available.
Sight Sciences, Inc. (SGHT) is a healthcare company in the targeted healthcare equipment industry, based in Menlo Park, United States, with about 186 full-time employees.
It reported revenue of $79.87 million for fiscal year 2024, down 1.5% from fiscal year 2023, and net income of -$51.51 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $19.91 million, down 1.2% from a year before. Its largest business segment, Interventional Glaucoma, brought in 98% of segment revenue in fiscal year 2025. Its market capitalization was $489.73 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye.
Sight Sciences reported $79.87 million in revenue for fiscal year 2024, down 1.5% from $81.06 million in fiscal year 2023. In Q3 2025 revenue was $19.91 million.
Interventional Glaucoma, with $75.72 million or 98% of segment revenue in fiscal year 2025. Next: Interventional Dry Eye (2%).
$489.73 million as of October 9, 2026.
Listed companies of a similar size in the same industry (targeted healthcare equipment) include Integra LifeSciences Holdings Corporation (IART), Ceribell, Inc. (CBLL), Tactile Systems Technology, Inc. (TCMD), BrainsWay Ltd. (BWAY).